Your browser doesn't support javascript.
Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi Arabia.
Banjar, Ayman; Al-Tawfiq, Jaffar A; Alruwaily, Amaal; Alserehi, Haleema; Al-Qunaibet, Ada; Alaswad, Rehab; Almutlaq, Hind; Almudaiheem, Abdullah; Khojah, Abdullah T; Alsaif, Faisal; Almolad, Shaza Karim; Alqahtani, Saeed; AlJurayyan, Abdullah; Alotaibi, Abdullah; Almalki, Safar; Abuhaimed, Yousef; Alkhashan, Abdullah; Alfaifi, Amal; Alabdulkareem, Khaled; Jokhdar, Hani; Assiri, Abdullah; Almudarra, Sami.
  • Banjar A; Deputy Ministry for Public Health, Ministry of Health, Riyadh, Saudi Arabia.
  • Al-Tawfiq JA; Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Infectious Disease Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Infectious Disease Division, Department of Medicine, Johns Hopkins Universi
  • Alruwaily A; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
  • Alserehi H; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
  • Al-Qunaibet A; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
  • Alaswad R; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
  • Almutlaq H; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
  • Almudaiheem A; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
  • Khojah AT; Faculty of Medicine, Al Imam Muhammad ibn Saud Islamic University, Riyadh, Saudi Arabia.
  • Alsaif F; Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Almolad SK; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia.
  • Alqahtani S; Deputy Ministry for Laboratories and Blood Banks, Ministry of Health, Riyadh, Saudi Arabia.
  • AlJurayyan A; King Fahad Medical City, Ministry of Health, Riyadh, Saudi Arabia.
  • Alotaibi A; Dammam Regional Laboratory, Ministry of Health, Dammam, Saudi Arabia.
  • Almalki S; Jeddah Regional Laboratory, Ministry of Health, Jeddah, Saudi Arabia.
  • Abuhaimed Y; King Saud bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia.
  • Alkhashan A; Deputy Ministry for Laboratories and Blood Banks, Ministry of Health, Riyadh, Saudi Arabia.
  • Alfaifi A; Deputy Ministry for Public Health, Ministry of Health, Riyadh, Saudi Arabia.
  • Alabdulkareem K; Deputy Ministry for Public Health, Ministry of Health, Riyadh, Saudi Arabia; Faculty of Medicine, Al Imam Muhammad ibn Saud Islamic University, Riyadh, Saudi Arabia.
  • Jokhdar H; Deputy Ministry for Public Health, Ministry of Health, Riyadh, Saudi Arabia.
  • Assiri A; Deputy Ministry for Public Health, Ministry of Health, Riyadh, Saudi Arabia.
  • Almudarra S; Deputy Ministry for Public Health, Ministry of Health, Riyadh, Saudi Arabia; Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia. Electronic address: salmudarra@moh.gov.sa.
Int J Infect Dis ; 104: 452-457, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1071447
ABSTRACT

BACKGROUND:

Serologic testing provides better understanding of SARS-CoV-2 prevalence and its transmission. This study was an investigation of the prevalence of antibodies to SARS-CoV-2 among blood donors in Saudi Arabia.

OBJECTIVE:

To estimate the seroprevalence of anti-SARS-CoV-2 antibodies among blood donors in Saudi Arabia during the early phase of the COVID-19 pandemic.

METHODS:

Serology results and epidemiological data were analyzed for 837 adult blood donors, with no confirmed SARS-CoV-2 infection, in Saudi Arabia from 20th to 25th May 2020. Seroprevalence was determined using electrochemical immunoassay to detect anti-SARS-CoV-2 antibodies.

RESULTS:

The overall seroprevalence of anti-SARS-CoV-2 antibodies was 1.4% (12/837). Non-citizens had higher seroprevalence compared with citizens (OR 13.6, p = 0.001). Secondary education was significantly associated with higher seroprevalence compared with higher education (OR 6.8, p = 0.005). The data showed that the highest seroprevalence was in Makkah (8.1%). Uisng Makkah seroprevalence as the reference, the seroprevalence in other areas was Madinah 4.1% (OR 0.48, 95% CI 0.12-1.94), Jeddah 2.3% (OR 0.27, 95% CI 0.31-2.25), and Qassim 2.9 % (OR 0.34, 95% CI 0.04-2.89) and these were not statistically different from seroprevalence in the Makkah region.

CONCLUSIONS:

At the early months of the COVID-19 pandemic in Saudi Arabia, the seroprevalence of antibodies to SARS-CoV-2 among blood donors was low, but was higher among non-citizens. These findings may indicate that non-citizens and less educated individuals may be less attentive to preventive measures. Monitoring seroprevalence trends over time require repeated sampling.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Donors / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: J.ijid.2021.01.028

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Donors / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: J.ijid.2021.01.028